Biotech Banter: Is This Pharma Giant a Keeper?
Merck (NYS: MRK) , a well-known dividend stock and longtime Dow component, is of interest to many investors throughout the world. However, as with any investment, there are compelling reasons to both buy and sell this stock.
In the following video, health-care analysts Max Macaluso and David Williamson take a close look at both sides of the coin and debate the importance of Merck's losing patent protection for its leading asthma drug, Singulair.
For nearly 100 years, Merck's cutting-edge research has led to a number of medical breakthroughs. Today, however, this pharma stalwart is staring down a steep patent cliff and facing generic competition for its top-selling drug. Will Merck crumble under its own weight, or will it continue to pay dividends to investors for another century? To find out if this pharma giant has the stamina to keep its Bunsen burners alight, grab your copy of our brand new premium research report today. Our senior biotech analyst Brian Orelli, Ph.D., walks you through both the opportunities and threats facing Merck, and the report comes with a full 12 months of updates. Claim your copy now by clicking here.
The article Biotech Banter: Is This Pharma Giant a Keeper? originally appeared on Fool.com.David Williamson owns shares of Pfizer. Max Macaluso, Ph.D., and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.